Volume 7, Number 2—April 2001
THEME ISSUE
4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections
State of the Art
Increasing Resistance to Vancomycin and Other Glycopeptides in Staphylococcus aureus
Table 3
Resistance patterns of staphylococcal study isolates to commonly tested antimicrobial agentsa
| Isolate (source) | Resistant or intermediateb | Susceptible |
|---|---|---|
| Staphylococcus aureus (Michigan) | Cd, Cip, E, Gm, Ox, P | C, L, Q-D, Rif, SXT, T |
| S. aureus (New Jersey) | Cd, Cip, E, Ox, P, Rif | C, Gm, L, Q-D, SXT, T |
| S. aureus (New York) | Cip, E, Ox, P, Rif | C, Cd, Gm, L, Q-D, SXT, T |
| S. aureus (Illinois) | C(I), Cd, Cip, E, Ox, P, Rif | L, Q-D, SXT, T |
| S. aureus (Germany) | Ak, Cd, Cip, E, Gm, Ox, P, Te | Fu, Ne |
| S. aureus (France, LIM-2) | C, Cd, Cip, E, Ox, P, Rif, Te | C, L, Q-D, SXT |
aAs determined using the broth microdilution reference method. bAbbreviations: C: chloramphenicol; Cd: clindamycin; Cip: ciprofloxacin; E: erythromycin; Fu: fusidic acid; Gm: gentamicin; L: linezolid; Ne: netilmycin; Ox: oxacillin; P: penicillin; Q-D, quinupristin-dalfopristin; Rif: rifampin; SXT: trimethoprim/ sulfamethoxazole; T: tetracycline. (I): intermediate. Based on data presented in references 20, 26, 32, and unpublished observations from CDC.
